Silence Therapeutics' RNAi Pipeline: Zerlasiran's Game-Changer Potential Is A 'Buy' [Seeking Alpha]
Silence Therapeutics Plc - American Depository Share (SLN)
Company Research
Source: Seeking Alpha
Summary Silence Therapeutics focuses on RNA interference therapies, with its lead candidates targeting cardiovascular and hematological diseases via the mRNAi GOLD platform. Zerlasiran, the company's main value driver, aims to reduce lipoprotein(a) levels, potentially lowering cardiovascular risks in 20-25% of the global population. Divesiran shows promise in early trials for Polycythemia Vera. Early clinical trial data suggests it can effectively regulate red blood cell production. SLNCF's partnerships with AstraZeneca and Hansoh Pharma validate its IP and could lead to significant milestone payments. Despite a premium valuation, SLNCF's ample resources and Zerlasiran's potential justify a "Buy" rating for investors understanding biotech risks. Pathompong Thongsan/iStock via Getty Images Silence Therapeutics plc ( NASDAQ: SLN ) develops RNA interference ("RNAI") therapies that silence genes associated with various diseases. SLN employs its proprietary mRNAi GOLD platfo
Show less
Read more
Impact Snapshot
Event Time:
SLN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SLN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SLN alerts
High impacting Silence Therapeutics Plc - American Depository Share news events
Weekly update
A roundup of the hottest topics
SLN
News
- RNA-Based Therapeutics Market to Grow by USD 1.27 Billion (2024-2028) Due to Increased Investment and Funding, AI Trends Impacting Revenue - TechnavioPR Newswire
- Silence Therapeutics plc (NASDAQ: SLN) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $40.00 price target on the stock.MarketBeat
- Silence Therapeutics plc (NASDAQ: SLN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.MarketBeat
- Silence Therapeutics to Webcast Presentations at Upcoming September Investor ConferencesBusiness Wire
- Silence Therapeutics plc (NASDAQ:SLN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report [Yahoo! Finance]Yahoo! Finance
SLN
Sec Filings
- 8/15/24 - Form 6-K
- 8/2/24 - Form SC
- 6/27/24 - Form 6-K
- SLN's page on the SEC website